Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma

Leukemia and Lymphoma

Volumn 34, Issue 1-2, 1999, Pages 185-190

  Varadi, Gabor ^a   Or, Reuven ^a   Kapelushnik, Joseph ^a   Naparstek, Elisabeth ^a   Nagler, Arnon ^a   Brautbar, Chaim ^a   Amar, Avraham ^a   Kirschbaum, Mark ^a   Samuel, Simcha ^a   Slavin, Shimon ^a   Siegal, Tali ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic peripheral blood stem cell transplantation; Graft versus lymphoma effect; Primary central nervous system lymphoma

Indexed keywords

ADULT; ALLOGRAFT; ARTICLE; BRAIN LYMPHOMA; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHIMERA; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LIVER DISEASE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SKIN DISEASE;

EID: 0033037567     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909083396     Document Type: Article

References (35)

1. Thomas, E.D. (1982). Kettering Award Lecture: The role of marrow transplantation in the eradication of malignant disease. Cancer, 49, 1963-1969, 1982.
2. O'Reilly, R.J. (1983). Allogeneic bone marrow transplantation: Current status and future directions. Blood, 62, 941-964.
3. Barrett, A.J., Horowitz, M.M., Gale, R.P., Biggs, J.C., Camitta B.M., Dicke K.A., Gluckman E, Good R.A., Herzig, R.H., Lee, M.B. (1989). Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood, 74: 862-871.
4. Horowitz, M.M., Gale, R.P., Sonde, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C. and Speck, B. (1990). Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-562.
5. Weiss, L., Weigensberg, M., Morecki, S., Bar, S., Cobbold, S., Waldmann, H. and Slavin S. (1990). Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunology and Immunotherapy, 31, 236-242.
6. Slavin, S., Ackerstein, A., Weiss, L., Nagler, A., Or, R. and Naparstek, E. (1992). Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Investigations, 10, 221-227.
7. Weiss, L., Lubin, I., Factorowich, I., Lapidot, Z., Reich, S., Reisner, Y. and Slavin, S. (1994). Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma: Role of cell therapy and recombinant IL-2. Journal of Immunology, 153, 2562-2567.
8. Truitt, R.L., Shih, C.Y., LeFever, A.V., Tempelis, L.D., Andreani, M. and Bortin, M.M. (1983). Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. Journal of Immunology, 131, 2050-2058.
9. Cohen, P., Vourka-Karussis, U., Weiss, L. and Slavin, S. (1993). Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. Journal of Immunology, 151, 4803-4810.
10. Collins, R.H. Jr., Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J.H. and Nemunaitis, J. (1997). Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology, 15, 433-444.
11. Naparstek, E., Nagler, A., Or, R., Kapelushnik, J. and Slavin, S. (1996). Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation. In Clinical Transplants, edited by JM Cecka and PI Terasaki, Chap 24. Los Angeles: UCLA Tissue Typing Laboratory.
12. Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Samuel, S., Kapelushnik, J., Brautbar, C. and Or, R. (1996). Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87, 2195-2204.
13. Ratanatharathorn, V., Ubertu, J., Karanes, C., Abella, E., Lum, A.G., Momin, F., Cummings, G. and Sensenbrenner, L.L. (1994). Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood, 84, 1050-1055.
14. Van Besien, K.W., Mehra, R.C., Giralt, S.A., Kantarjian, H.M., Pugh, W.C., Khouri, I.F., Moon, Y., Williams, P., Andersson, B.S. and Przepiorka, D. (1996). Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology. American Journal of Medicine, 100, 299-307.
15. Tricot, G., Vesole, D.H., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996). Graft-versus-myeloma effect: proof of principle. Blood, 87, 11961198.
16. Eibl, B., Schwaighofer, H., Nachbaur, D., Marth, C., Gachter, A., Knapp, R., Bock, G., Gassner, C., Schiller, L., Petersen, F. and Niederwieser, D. (1996). Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood, 88, 1501-1508.
17. Rapoport, A.P., Rowe, J.M., Kouides, P.A., Duerst, R.A., Abboud, C.N., Liesveld, J.L., Packman, C.H., Eberly, S., Sherman, M. and Tanner, M.A. (1993). One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. Journal of Clinical Oncology, 11, 2351-2361.
18. Armitage, J.O. (1993). Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1023-1030.
19. Ferreri, A.J., Reni, M. and Villa, E. (1995). Primary central nervous system lymphoma in immunocompetent patients. Cancer Treatment Review, 21, 415-446.
20. Fine, H.A. and Mayer, R.J. (1993). Primary central nervous system lymphoma. Annals of Internal Medicine, 119, 1093-1110.
21. Fine, H.A. (1996). Treatment of primary central nervous system lymphoma: Still more questions than answers. Blood, 86, 2873-2875.
22. Chopra, R., Goldstone, A.M., Pearce, R., Philip, T., Petersen, F., Appelbaum, F., De Vol, E. and Ernst, P. (1995). Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group registry data. Journal of Clinical Oncology, 10, 1690-1695.
23. Naparstek, E., Or, R., Nagler, A., Cividalli, G., Engelhard, D., Aker, M., Gimon, Z., Manny, N., Sacks, T., Tochner, Z., Weiss, L., Samuel, S., Brautbar, C., Hale, G., Waldman, H., Steinberg, S.M. and Slavin, S. (1995). T-cell-depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. British Journal of Haematology, 89, 506-515.
24. Johnson, B.D., Drobyski, W.R. and Truitt, R.L. (1993). Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplantation, 11, 329-336.
25. Kolb, H.J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. and Wilmanns, W. (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462-2465.
26. Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Kapelushnik, J. and Or R. (1995). Allogneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Experimental Hematology, 23, 1553-1562.
27. Kapelushnik, J., Nagler, A., Or, R., Naparstek, E., Ackerstein, A., Samuel, S., Morecki, S., Nabel, C. and Slavin, S. (1996). Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions postallogeneic bone marrow transplantation. Bone Marrow Transplantation, 18, 1153-1156.
28. Shlomchik, W.D. and Emerson, S.O. (1996). The immunobiology of T cell therapies for leukemias. Acta Haematologica, 96, 189-213.
29. Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Korbling, M., Keating, M., Kantarjian, H. and Champlin, R. (1997). Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89, 4531-4536.
30. Bar, B.M., Schattenberg, A., Mensink, E.J., Geurts-Van Kessel, A., Smetsers, T.F., Knops, G.H., Linders, E.H. and De Witte, T. (1993). Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. Journal of Clinical Oncology, 11, 513-519.
31. [31 ] Drobyski, W.R., Roth, M.S., Thibodeau, S.N. and Gottschall, J.L. (1992). Molecular remission occurring after donor leukecyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 10, 301-304.
32. Drobyski, W.R., Keever, C.A., Roth, M.S., Koethe, S., Hanson, G., McFadden, P., Gottschall, J.L., Ash, R.C., van Tuinen, P. and Horowitz, M.M. (1993). Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood, 82, 2310-2318.
33. Williams, K.C. and Hickey, W.F. (1995). Traffic of hematogenous cells through the central nervous system. Current Topics in Microbiology and Immunology, 202, 221-245.
34. Lassmann, H., Schmied, M., Vass, K. and Hickey, W.F. (1993). Bone marrow derived elements and resident microglia in brain inflammation. Glia, 7, 19-24.
35. Krivit, W., Sung, J.H., Shapiro, E.G. and Lockman, L.A. (1995). Microglia: The effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplantation, 4, 385-392.